Background: Burn wound infection is one of the most frequent and major complications in patients with burn injuries and is the main cause for prolonged in-hospital stay and death in cases of wide-spread infection. The purpose of this study is to investigate the effects of semipermeable membranes( ActicoatTM) in deep partial thickness burns in comparison to standard care silver sulfadiazine DermazineTM . Patients and methods: In a prospective study design included n=30 severely injured patients with superficial to deep partial thickness burns they were randomized into two groups, group A (ActicoatTM) (n=15) and group B receiving treatment with standard silver sulfadiazine (DermazineTM) (n = 15) .The outcome measures were pain ,temperature , time of wound healing, and Scar quality. Results: There were significant differences between the two groups. Regard to, time to re-epithelialization and Scar quality in favor of (ActicoatTM) treatment group versus (DermazineTM) group (p < 0.005) Conclusion: In this study, we demonstrated that the choice of medication or membrane for a burn wound is a never-ending source of discussion and fortunately, most medications (DermazineTM) and membranes (ActicoatTM) perform well if physicians carefully monitor wounds, keep them clean, prevent desiccation, and properly manage secondary infection.
(2018). EARLY BURN WOUND MANAGEMENT; WOUND MEMBRANES (ACTICOATTM) VERSUS STANDARD SILVER SULFADIAZINE (DERMAZINETM). Zagazig University Medical Journal, 24(7), 51-56. doi: 10.21608/zumj.2018.31568
MLA
. "EARLY BURN WOUND MANAGEMENT; WOUND MEMBRANES (ACTICOATTM) VERSUS STANDARD SILVER SULFADIAZINE (DERMAZINETM)". Zagazig University Medical Journal, 24, 7, 2018, 51-56. doi: 10.21608/zumj.2018.31568
HARVARD
(2018). 'EARLY BURN WOUND MANAGEMENT; WOUND MEMBRANES (ACTICOATTM) VERSUS STANDARD SILVER SULFADIAZINE (DERMAZINETM)', Zagazig University Medical Journal, 24(7), pp. 51-56. doi: 10.21608/zumj.2018.31568
VANCOUVER
EARLY BURN WOUND MANAGEMENT; WOUND MEMBRANES (ACTICOATTM) VERSUS STANDARD SILVER SULFADIAZINE (DERMAZINETM). Zagazig University Medical Journal, 2018; 24(7): 51-56. doi: 10.21608/zumj.2018.31568